Myriad Genetics (MYGN) Expected to Announce Earnings on Tuesday

Myriad Genetics (NASDAQ:MYGN - Get Free Report) is anticipated to post its Q1 2025 quarterly earnings results after the market closes on Tuesday, May 6th. Analysts expect Myriad Genetics to post earnings of ($0.05) per share and revenue of $200.37 million for the quarter.

Myriad Genetics (NASDAQ:MYGN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.12). Myriad Genetics had a negative return on equity of 4.51% and a negative net margin of 14.09%. The company had revenue of $210.60 million during the quarter, compared to analyst estimates of $210.35 million. During the same quarter in the prior year, the business earned ($0.12) earnings per share. On average, analysts expect Myriad Genetics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Myriad Genetics Stock Performance

Shares of NASDAQ MYGN traded up $0.43 during mid-day trading on Friday, hitting $7.56. The company had a trading volume of 2,311,317 shares, compared to its average volume of 983,994. Myriad Genetics has a 12 month low of $6.94 and a 12 month high of $29.30. The firm has a market cap of $696.81 million, a P/E ratio of -5.82 and a beta of 1.87. The business's 50-day simple moving average is $8.89 and its 200-day simple moving average is $13.10. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.90 and a quick ratio of 1.73.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Stephens restated an "equal weight" rating and issued a $20.00 target price on shares of Myriad Genetics in a research note on Thursday, January 16th. StockNews.com raised shares of Myriad Genetics from a "hold" rating to a "buy" rating in a report on Thursday, April 10th. Piper Sandler raised shares of Myriad Genetics from a "neutral" rating to an "overweight" rating and upped their target price for the company from $11.50 to $12.50 in a research note on Wednesday, March 12th. The Goldman Sachs Group dropped their price target on shares of Myriad Genetics from $18.00 to $14.00 and set a "buy" rating for the company in a research report on Thursday, April 17th. Finally, UBS Group lowered their price objective on Myriad Genetics from $18.00 to $16.00 and set a "neutral" rating on the stock in a research note on Tuesday, February 25th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, Myriad Genetics currently has an average rating of "Hold" and an average target price of $20.61.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.